Relapse surged when maintenance therapy was withdrawn in stable IgG4-RD
In stable IgG4-related disease, the WInS IgG4-RD trial delivered a blunt message: stopping both glucocorticoids and immunosuppressants was followed by substantially more relapses than continuing maintenance therapy. The study tested a question clinicians face often in fibroinflammatory disease control — whether a patient who has settled into clinical quiescence for at least a year can safely come off treatment without paying for it later in the form of recurrent organ inflammation.
That answer was not reassuring for full withdrawal. Within 18 months, relapse occurred in 25 of 48 patients, or 52.1%, in the group that withdrew both glucocorticoids and immunosuppressants. By contrast, relapse was far less frequent in the groups that kept immunosuppressive therapy in place: 7 of 49 patients, or 14.2%, when glucocorticoids were stopped but immunosuppressants were maintained, and 6 of 49 patients, or 12.2%, when both therapies were continued.
A three-arm design tested withdrawal at the bedside
The trial was investigator-initiated, multicentre, open-label, and randomized. Patients entered only after demonstrating clinically quiescent disease for at least 12 months while receiving glucocorticoid plus immunosuppressant maintenance treatment. Randomization split the cohort into three practical strategies that mirror real-world decisions in rheumatology and related immune-mediated practice: stop both drugs, stop only glucocorticoids while holding the immunosuppressant, or continue both.
The primary endpoint was relapse within 18 months. Secondary measures included the IgG4-RD Responder Index, Physician’s Global Assessment, serum IgG4 and total IgG, and adverse events. Even in a disease where symptoms can quiet down while tissue-level inflammation lingers, this framework is clinically sensible. IgG4-RD is not a transient inflammatory episode; it is a chronic immune-mediated fibroinflammatory disorder in which relapse can mean renewed damage to pancreas, salivary glands, bile ducts, kidneys, retroperitoneum, or other involved organs.
Full withdrawal carried the heaviest relapse burden
The pattern across the arms was difficult to ignore. Patients who stopped everything had about one relapse for every two participants during follow-up. The two groups that retained immunosuppression were far more stable, and the difference was large enough to suggest that ongoing immunomodulation, rather than glucocorticoid exposure alone, was doing much of the heavy lifting in suppressing recurrent disease activity.
A single sentence captures the practical consequence: complete withdrawal was the highest-risk strategy.
That finding fits the biology of IgG4-RD. The disease is driven by immune dysregulation that can persist even when clinical findings settle and laboratory markers look improved. Fibroinflammatory lesions may remain poised for reactivation, and glucocorticoids can suppress symptoms without erasing the underlying immune tendency toward relapse. If the maintenance immunosuppressant is the drug holding that inflammatory circuitry in check, removing it may expose latent disease activity that had simply been muted rather than extinguished.
Why glucocorticoid withdrawal alone may be less dangerous than stopping everything
The two arms that preserved immunosuppressive treatment had similarly low relapse rates, whether glucocorticoids were continued or withdrawn. Clinically, that matters because chronic glucocorticoid exposure carries well-known toxicity: metabolic disturbance, infection risk, bone loss, weight gain, hypertension, and the cumulative burden of steroid dependence. A regimen that allows steroid tapering while maintaining immunosuppression can therefore preserve disease control while reducing steroid exposure.
This is the most actionable therapeutic signal in the trial. For patients who have remained stable for at least a year, the data argue against assuming that remission permits complete drug cessation. They also suggest that the more realistic off-ramp may be steroid withdrawal with continued maintenance immunosuppression, rather than stopping both agents at once.
The study did not suggest that all maintenance therapy should continue indefinitely for every patient. It did show, with striking simplicity, that the safest of the three tested approaches was not total withdrawal.
Biomarker and clinical assessments were built into the relapse question
The use of IgG4-RD Responder Index, Physician’s Global Assessment, and serum IgG4 and IgG provided a clinically grounded way to track disease beyond a binary relapse yes-or-no endpoint. In a condition like IgG4-RD, serologies and physician assessment can sometimes provide early warning before overt organ dysfunction emerges. They also help distinguish symptomatic improvement from genuine immunologic quiescence. Even so, the primary readout remained relapse, and the relapse pattern dominated the story.
Because the trial population had already achieved at least 12 months of clinical quiescence on maintenance therapy, these results apply to a relatively stable group rather than to newly diagnosed or highly active disease. That makes the findings especially relevant to the long maintenance phase, where treatment fatigue, adverse effects, and the wish to simplify therapy often push both clinicians and patients toward dose reduction or drug discontinuation.
Maintenance decisions in IgG4-RD now look less discretionary
The trial places a practical boundary around de-escalation in IgG4-related disease. Complete discontinuation after a stable year was associated with far more relapse than either continuing glucocorticoids and immunosuppressants together or stopping glucocorticoids alone while keeping immunosuppression in place. For clinicians, this means the discussion about tapering should not be framed as a general “can we stop everything?” question. It should focus on which agent can be removed first without reopening the inflammatory process.
For patients, the distinction is concrete. A relapse in IgG4-RD can mean repeat imaging, repeat laboratory monitoring, renewed organ compromise, and often reintroduction of glucocorticoids that had been intentionally minimized. Preventing that cycle is one reason maintenance therapy exists in the first place.
The trial still leaves open how long immunosuppressive therapy should be continued once glucocorticoids are stopped, and which subgroups are most likely to remain relapse-free after de-escalation. Even so, the central clinical signal is hard to miss: in stable IgG4-RD, stopping both maintenance drugs invited relapse far more often than keeping immunosuppression on board.